SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-032094
Filing Date
2022-11-14
Accepted
2022-11-14 16:27:16
Documents
68
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1279106
2 ex31-1.htm EX-31.1 19219
3 ex31-2.htm EX-31.2 18971
4 ex32-1.htm EX-32.1 8793
5 ex32-2.htm EX-32.2 8999
  Complete submission text file 0001493152-22-032094.txt   6970172

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ensc-20220930.xsd EX-101.SCH 48248
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ensc-20220930_cal.xml EX-101.CAL 61012
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ensc-20220930_def.xml EX-101.DEF 257619
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ensc-20220930_lab.xml EX-101.LAB 438360
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ensc-20220930_pre.xml EX-101.PRE 355435
62 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1130697
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38306 | Film No.: 221386211
SIC: 2834 Pharmaceutical Preparations